✦ LIBER ✦

Prevention of Bone Loss by Clodronate in Early Postmenopausal Women with Vertebral Osteopenia: A Dose-Finding Study

✍ Scribed by M. J. Välimäki; K. Laitinen; K. Laitinen; A. Patronen; H. Puolijoki; H. Puolijoki; J. Seppänen; L. Pylkkänenand the Probone Study Group*

Publisher: Springer-Verlag
Year: 2002
Tongue: English
Weight: 314 KB
Volume: 13
Category: Article
ISSN: 0937-941X
DOI: 10.1007/s001980200131

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Retrospective Case–Control Study Asses

A Retrospective Case–Control Study Assessing the Role of Trabecular Bone Score in Postmenopausal Caucasian Women with Osteopenia: Analyzing the Odds of Vertebral Fracture

✍ Renaud Winzenrieth; Rémy Dufour; Laurent Pothuaud; Didier Hans 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 199 KB

Vitamin D and HRT: No benefit additional

Vitamin D and HRT: No benefit additional to that of HRT alone in prevention of bone loss in early postmenopausal women. A 2.5-year randomized placebo-controlled study

✍ M. Komulainen; M. T. Tuppurainen; H. Kröger; A. M. Heikkinen; E. Puntila; E. Alh 📂 Article 📅 1997 🏛 Springer-Verlag 🌐 English ⚖ 865 KB

Effective inhibition of aromatase inhibi

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole : ZO-FAST study results

✍ Nigel J. Bundred; Ian D. Campbell; Neville Davidson; Richard H. DeBoer; Holger E 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB

## Abstract ## BACKGROUND. Letrozole is safe and effective in postmenopausal women with estrogen receptor‐positive early breast cancer, but long‐term aromatase inhibitor use may cause bone loss and increase fracture risk. This study evaluated an immediate or delayed strategy of bone protection the